+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Healthcare Licensing - Country Trends: United States (Pharmaceuticals MidCap) Mid-Year Review

  • ID: 4604834
  • Report
  • July 2018
  • Region: Global, United States
  • 45 pages
  • FinGlobe, Inc
1 of 2
This mid-year review report brings at one place all the news for licensing deals and negotiations that took place for the pharmaceuticals midcap companies of United States during January 1, 2018 to June 30, 2018. The licensing trends and directions during this time period are also analyzed comprehensively.

Key Features:
  • 6 months’ healthcare licensing news for United States pharmaceuticals midcap companies at one place
  • Multinational/non-multinational companies covered
  • Curated categorizations of licensing news
  • 8+ variables reflecting different forms of transactions done
  • Licensing trends and directions summarized
The Report is useful to:
  • United States pharmaceuticals midcap companies and other countries’ healthcare companies planning to introduce products in each other’s markets
  • Companies active in R&D and seeking new market base
  • Healthcare company executives negotiating licensing deals between United States pharmaceuticals midcap and other countries’ companies worldwide
  • Investors analyzing varied kinds of transaction options for licensing deals
Key analysis provided: January-June 2018
  • Total number of licensing deals from United States pharmaceuticals midcap companies to other countries’ companies
  • Total number of licensing deals from other countries’ companies to United States pharmaceuticals midcap companies
  • Total number of companies/institutes involved in United States (Pharmaceuticals Midcap) licensing deals
  • Most licensing deals signed by which countries with United States pharmaceuticals midcap companies
  • Most licensing deals signed by which medicine groups
  • Licensing payment arrangements most followed in the licensing deals between United States pharmaceuticals midcap and other countries’ companies
  • Number of domestic and worldwide licensing between United States pharmaceuticals midcap and other countries’ companies
  • Number of R&D and commercialization licensing between United States pharmaceuticals midcap and other countries’ companies
  • Number of licensing deals discontinued between United States pharmaceuticals midcap and other countries’ companies
Note: Product cover images may vary from those shown
2 of 2
Introduction

Research Design

Section 1: Healthcare inventions licensed by United States (Pharmaceuticals MidCap) companies to other countries
1.1 By United States company name
1.2 By Other country company name
1.3 By Terms of payment
1.4 By Medical groups

Section 2: Healthcare inventions licensed by other countries to United States (Pharmaceuticals MidCap) companies
2.1 By Other country company name
2.2 By United States company name
2.3 By Terms of payment
2.4 By Medical groups

Section 3: Healthcare inventions licensed within United States for United States (Pharmaceuticals MidCap) companies

Section 4: Trends in United States (Pharmaceuticals MidCap) licensing deals
4.1 Countries with most licensing deals with United States (Pharmaceuticals MidCap) companies
4.2 Healthcare companies most active in outbound and inbound licensing deals
4.3 Medical groups most active in licensing deals
4.4 Licensing payment arrangements most followed
4.5 Worldwide licensing vs domestic licensing
4.6 R&D licensing vs commercialization licensing
4.7 Licensing deals which discontinued

Section 5: Trends and directions

Appendices
Appendix 1 List of United States-based companies/institutes covered in this report
Appendix 2 List of other countries’ companies/institutes covered in this report
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll